ErbB receptors are primarily thought to signal as homo- and heterodimers with other ErbB receptors2, but interactions of ErbB receptors with Met3 and IGF-1R4 RTKs (“non-canonical” interactions) have been reported, particularly in cells that have acquired resistance to ErbB-targeting anti-cancer drugs. The gene discussed is EGFR; the disease is cancer.